|
DGAP-Ad-hoc: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Personnel
B.R.A.I.N. Biotechnology Research And Information Network AG: Resignation of the member of the Supervisory Board Dr. Marquart
27-Feb-2020 / 14:21 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
BRAIN AG: Resignation of the member of the Supervisory Board Dr. Marquart
Zwingenberg, Germany
27 February 2020
The Management Board of the B.R.A.I.N. Biotechnology Research and Information Network AG announces that Dr. Rainer Marquart, previously a member of the Supervisory Board of the company, has resigned from the Supervisory Board with immediate effect today.
Notifying person:
Martina Schuster, Investor Relations
B.R.A.I.N. Biotechnology Research and Information Network AG
Darmstädter Str. 34-36, 64673 Zwingenberg, Germany
www.brain-biotech.com
Investor Relations Office
Tel.: +49-(0)-6251-9331-0
Fax: +49-(0)-6251-9331-11
E-Mail: ir@brain-biotech.com
+++END+++
Information and Explanation of the Issuer to this News:
About BRAIN
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this 'Toolbox of Nature' are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the 'Tailor-Made Solutions' cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.de/en.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
27-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
